Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume

Cancer

Volumn 71, Issue 6, 1993, Pages 2031-2040

  Schmid, Hans‐Peter ^a   McNeal, John E ^a   Stamey, Thomas A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

doubling time; growth pattern; prostate cancer; serial prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DIAGNOSTIC VALUE; GROWTH CURVE; GROWTH RATE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CELL DIVISION; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0027465152     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q     Document Type: Article

References (29)

1. Latent carcinoma of the prostate
2. Histologic differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate
3. Patterns of progression in prostatic carcinoma
4. Morphometric and clinical studies on 68 consecutive radical prostatectomies
5. Prostate‐specific antigen as a serum marker for adenocarcinoma of the prostate
6. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. radical prostatectomy treated patients
7. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. untreated patients
8. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice
9. Origin and development of carcinoma in the prostate
10. Capsular penetration in prostate cancer: significance for natural history and treatment
11. Pathogenesis and biologic significance of seminal vesicle invasion in prostatic carcinoma
12. Measurement of prostate specific antigen in serum as a screening test for prostate cancer
13. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer
14. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate
15. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
16. Prostate‐specific antigen, digital rectal examination, and transrectal ultrasonic examination of the prostate in prostate cancer detection
17. Expectant management of localized prostatic cancer
18. Radical perineal prostatectomy for palpable, clinically localized, non‐obstructive cancer: experience at the Johns Hopkins Hospital 1909–1963
19. Total prostatectomy for localized prostatic cancer
20. Status of radiation treatment of prostate cancer at Stanford University
21. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old
22. High 10‐year survival rate in patients with early, untreated prostatic cancer
23. Circulating prostate‐specific antigen in benign hypertrophy and localized cancer of the prostate: can PSA be considered as a screening examination for localized cancer?
24. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations
25. Growth rate patterns of solid tumors and their relation to responsiveness to therapy
26. Association between the actual doubling times of primary breast cancer with histopathologic characteristics and Wolfe's parenchymal mammographic patterns
27. Longitudinal evaluation of prostate‐specific antigen levels in men with and without prostate disease
28. Estimation of prostatic growth using serial prostate‐specific antigen measurements in men with and without prostate disease